Figure 2.

Therapeutic response assessment. Early demonstration of response to expensive targeted therapies can either reassure a patient of the value of this treatment or allow a change in management. This patient with mutant BRAF-expressing melanoma was started on vemurafanib, with an excellent early metabolic response and partial radiologic response. Although this was subsequently matched by further significant regression of disease on CT, reactivation of glycolytic metabolism was an early manifestation of developing resistance to treatment.